Big pharma under the spotlight.

B. Farham
DOI: https://doi.org/10.7196/samj.6991
2013-05-22
Abstract:In February 2013, in what the British Medical Journal called a 'spectacular public relations coup', Andrew Witty, the chief executive officer of GlaxoSmithKline (GSK), announced that the company would sign up to AllTrials - a campaign that has been pressing drug companies to disclose all detailed clinical study reports and drug trial results, not just those with favourable results.
What problem does this paper attempt to address?